Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CEA CAR-T for Postoperative Colorectal Cancer
NCT04513431Phase 1Unknown
- Sponsor
- Ruijin Hospital
- Start
- Aug 2020
- Primary completion
- Mar 2021
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of CAR2 anti-CEA CAR-T cells in colorectal cancer (CRC), sponsored by Ruijin Hospital. Primary endpoint: Adverse events that related to treatment at 4 weeks. Status: unknown.
02
Drugs
CAR2 anti-CEA CAR-T cells
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04513431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513431.